RMD — ResMed Inc.

ResMed Q1 Fiscal Year 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.34 billion, up 9% year-over-year (8% on a constant currency basis).
• Gross Margin: 62%, an increase of 280 basis points year-over-year.
• Operating Profit: Increased by 19%, with an operating margin of 36.1%.
• Net Income: Increased by 15%, with non-GAAP diluted earnings per share up 16%.
• Cash Flow from Operations: $457 million, reflecting strong operational performance.
• Dividends and Share Buybacks: $238 million returned to shareholders, with a quarterly dividend of $0.60 per share.

2. Strategic Updates and Business Highlights

• Product Growth: Strong performance in devices (8% growth) and masks (12% growth) in the U.S., Canada, and Latin America.
• Residential Care Software (RCS): Mid-single-digit growth (6% reported, 5% constant currency), with a focus on optimizing higher-margin segments.
• Innovation: Launch of the AirTouch F30i full-face mask, expanding the mask portfolio and targeting comfort-driven patients.
• Digital Health Initiatives: Continued investment in AI and machine learning technologies, including the launch of the "Dawn" digital assistant for personalized patient support.
• Supply Chain Enhancements: Expansion of U.S. manufacturing capabilities, including a new distribution center in Indianapolis expected to be operational by 2027.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipated acceleration in growth for masks and accessories, with a target of returning to high single-digit growth in the Europe, Asia, and Rest of World segments.
• Gross Margin: Expected to remain between 61% to 63% for fiscal year 2026.
• Operating Expenses: SG&A expenses projected to be 19% to 20% of revenue, while R&D expenses are expected to remain at 6% to 7% of revenue.

4. Bad News, Challenges, or Points of Concern

• RCS Growth: The SaaS segment experienced slower growth than expected, attributed to a focus on lower-margin service areas which are being re-evaluated.
• Competitive Bidding Program: ResMed is preparing for the resumption of competitive bidding by CMS, which could impact pricing and market access.
• Tax Rate Increase: Effective tax rate increased to 22.3% due to global minimum tax legislation, which may affect net income.

5. Notable Q&A Insights

• Mask Launch: The new AirTouch F30i mask is positioned to capture a significant market share in the full-face category, with a focus on comfort and patient adherence.
• Patient Funnel Management: ResMed is actively working on improving the patient funnel through acquisitions like VirtuOx and NightOwl, aiming to reduce patient churn and enhance access to care.
• Market Penetration: Current U.S. market penetration for sleep apnea treatment is estimated at 15% to 20%, with significant room for growth as awareness increases.
• Future Acquisitions: ResMed is open to further tuck-in acquisitions to enhance its capabilities in the sleep health market, particularly in improving patient access and retention.

Overall, ResMed reported a strong quarter with solid growth across key segments, ongoing innovation, and strategic investments aimed at enhancing patient care and operational efficiency, despite facing challenges in certain areas like RCS growth and the upcoming competitive bidding program.